ArticleJournal of managed care & specialty pharmacy2026
Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025).
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdalimumab is a widely used biologic for autoimmune diseases. Biosimilars to adalimumab became available in 2023 and were expected to improve affordability and access, yet real-world evidence on switching after biosimilar initiation remains limited.
objectiveTo assess adoption of adalimumab biosimilars and characterize the frequency and timing of switch-backs to originator adalimumab.
methodsThis retrospective cohort study used Truveta Data, a deidentified electronic health record dataset. Adult patients were included if they had at least 1 outpatient or telehealth encounter between February 1, 2023, and August 31, 2025, and at least 2 originator adalimumab dispenses in the prior year. Switching was defined as the first biosimilar dispense following originator use, and switch-back was defined as a subsequent originator dispense after biosimilar initiation. Multivariable logistic regression identified characteristics associated with switch-back, and a Cox proportional hazards model evaluated factors associated with earlier switch-back (≤30 days).
resultsAmong 67,594 patients treated with originator adalimumab, 17.7% (n = 11,947) switched to a biosimilar during the study period. Switching peaked in April 2024, coinciding with formulary changes. Among 9,252 biosimilar initiators, with at least 1 clinical encounter at least 90 days after a biosimilar dispense, 16.0% (n = 1,478) switched back to the originator. Older adults (≥65 years and 50-64 years) had higher odds of switching back (odds ratio [OR] = 2.05 [95% CI = 1.64-2.56] and OR = 1.23 [95% CI = 1.03-1.46], respectively), as did women (OR = 1.19; 95% CI = 1.05-1.34) and patients with ankylosing spondylitis (OR = 1.32; 95% CI = 1.10-1.58). Rural residence was associated with higher odds of early switch-back (OR = 1.80; 95% CI = 1.20-2.70).
conclusionsBiosimilar uptake increased following formulary changes, yet more than 1 in 7 biosimilar initiators returned to originator adalimumab. Variation in early switch-back and patient characteristics highlights the importance of real-world evidence to understand biosimilar adoption beyond formulary-driven transitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.